Who are Saline + Ketamine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CI-581-a, CI-581-b.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/saline-ketamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Saline + Ketamine — Competitive Intelligence Brief

Saline + Ketamine (Saline + Ketamine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist / Dissociative anesthetic. Area: Anesthesia / Pain Management.

marketed NMDA receptor antagonist / Dissociative anesthetic NMDA receptor (glutamate-gated ion channel) Anesthesia / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Saline + Ketamine (Saline + Ketamine) — Ullevaal University Hospital. Ketamine blocks NMDA glutamate receptors in the central nervous system, producing rapid-onset dissociative anesthesia and analgesia when administered intravenously in saline solution.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Saline + Ketamine TARGET	Saline + Ketamine	Ullevaal University Hospital	marketed	NMDA receptor antagonist / Dissociative anesthetic	NMDA receptor (glutamate-gated ion channel)
CI-581-a	CI-581-a	New York State Psychiatric Institute	phase 3	NMDA receptor antagonist / Dissociative anesthetic	NMDA receptor
CI-581-b	CI-581-b	New York State Psychiatric Institute	phase 3	NMDA receptor antagonist / Dissociative anesthetic	NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist / Dissociative anesthetic class)

New York State Psychiatric Institute · 2 drugs in this class
Ullevaal University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Saline + Ketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/saline-ketamine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab